PAREXEL International Corporation, the world’s leading innovator of biopharmaceutical services, and Meiji Pharmaceutical University (MPU), a private pharmacy and science university located in Tokyo, Japan, announced a new Joint Program for Clinical Research and Clinical Trial Management for undergraduate students.
The academic program will offer MPU students an accredited, four-week course designed to prepare them for careers in the biopharmaceutical industry.
Designed to meet the growing demands of biopharmaceutical companies conducting clinical research both inside and outside of Japan, the collaborative program combines PAREXEL’s global clinical research expertise with MPU’s established pharmaceutical training experience. All classes will be conducted in English from PAREXEL Academy lecturers and are consistent with current global clinical trial standards and practices. Following a series of two-week pilot programs, the first official program will be offered in November 2019. In addition, select MPU students may be eligible for enrollment at the PAREXEL Academy in Berlin in the future.
For more than a decade, the PAREXEL Academy has designed and implemented a wide range of learning programs in clinical research for students in Asia, Europe, and the United States. PAREXEL’s collaboration with MPU is the company’s second academic program in Japan, following PAREXEL’s first program with Kyoto Pharmaceutical University which launched in early 2016. Since PAREXEL Academy’s inception, approximately 5,000 students have graduated from its programs.
PAREXEL established operations in Japan in 1995 and has more than 1,300 employees based in Tokyo, Kobe and Osaka. The Company provides clinical research services, consulting and technology offerings to biopharmaceutical companies.